This study aims to explore the
therapeutic effect of bone marrow mesenchymal stem cells on
adriamycin nephrosis, and the potential mechanism. The rat experimental nephropathy model was established by unilateral
nephrectomy combined repeated injecting
adriamycin (ADR). Thirty
adriamycin nephrosis rats were randomly divided into three groups, including ADR (n=10), MSCs
transplantation through peripheral veins groups (M-V, n=10), and MSCs
transplantation through right renal artery groups (M-A, n=10), and there was another normal control group (N, n=10). This study lasted 8 weeks, 24 hours urine was collected through simple metabolic cage to measure urinary volume and urine
protein quantitation in 24 hours. The levels of
plasma albumin (ALB),
sodium were measured by biochemical analysis. The expressions of AQP1-2 were measured by immuno-histochemistry assay. Kidney medulla ultramicroscopic structure was observed by TEM. The results indicated that the ALB and 24 h urinary volume have significant increased in M-V and M-A group compared to the ADR group (P<0.05). Furthermore, the serum
sodium and urine
protein quantitation in 24 hours were decreased in M-V and M-A group compared to ADR group (P<0.05).
Protein expression of AQP1-2 had been remarkably decreased (P<0.05). It showed degenerative changes of kidney ultra microscopic structures of the ADR rats, while MSCs
transplantation could significantly improve the damage. In conclusion, in
adriamycin nephropathy rats, MSCs
transplantation exerts its
therapeutic effects by decrease urinary
albumin excretion, increase ALB, decrease
sodium and the expression of AQP1-2 in renal tubules.